XOLAIR (OMALIZUMAB) (PREFERRED)
PRIOR AUTHORIZATION FORM

(form effective 7/30/20)

Fax to PerformRx℠ at **1-888-981-5202**, or to speak to a representative call **1-866-610-2774.**

PRIOR AUTHORIZATION REQUEST INFORMATION

☐ New request ☐ Renewal request	Total # pages:	Name of office contact:
Contact's phone number:		LTC facility contact/phone:

PATIENT INFORMATION

Patient name:	Patient ID #:	DOB:
Street address:	Apt. #:	City/state/zip:

PRESCRIBER INFORMATION

Prescriber name:		Specialty:
State license #:	NPI:	MA Provider ID #
Street address:	Suite #:	City/state/zip:
Phone:		Fax:

CLINICAL INFORMATION

Medication requested: ☐ Xolair 150 mg/ml syringe ☐ Xolair 150 mg vial ☐ Xolair 75 mg/0.5 ml syringe ☐ Xolair ___________________________

Dose/directions:	Quantity:	Duration: months
Diagnosis:	Dx code *(required)*:	Weight: lbs / kg

PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication, if applicable):

Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Patient's Preferred Pharmacy Name:

Pharmacy Phone #:	Pharmacy Fax #:

☐ I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.

HCPCS (HEALTHCARE COMMON PROCEDURE CODING SYSTEM) INFORMATION (if applicable):

Treatment setting: ☐ Infusion Center ☐ Home ☐ Provider's Office ☐ Hospital Outpatient Facility

Facility name:	Facility NPI:	
J-code:	Number of units:	Date of service (MM/DD/YYYY):

INITIAL REQUESTS

1. Is Xolair being prescribed by or in consultation with a specialist? ☐ Yes – *Provide specialty:*___________________________ ☐ No
2. **<u>For a diagnosis of asthma</u>**: Is the patient being treated for moderate to severe persistent asthma induced by an unavoidable perennial allergen (pollen, mold, dust mites, etc.) and inadequately controlled by inhaled corticosteroids? ☐ Yes – *Submit documentation, including results of allergen reactivity test.* ☐ No
3. **<u>For a diagnosis of asthma</u>**: Does the patient have a serum total IgE measurement between 30 international units (IU)/ml and 1300 IU/ml? ☐ Yes ☐ No
   IgE level:________________________ Date of result:________________________
4. **<u>For a diagnosis of asthma:</u>** Is the patient currently receiving optimally titrated doses, or have a contraindication or intolerance to, any of the following?
   ☐ inhaled glucocorticoid ☐ leukotriene modifier ☐ long-acting beta-agonist (LABA) ☐ other (e.g., tiotropium, theophylline): ____________________
   ☐ Yes – List medications being used: ____________________
   ☐ No
5. **<u>For a diagnosis of chronic idiopathic urticaria (CIU):</u>** Does the patient have a history of urticaria for a period of ≥ 3 months? ☐ Yes – *Submit documentation.* ☐ No
6. For a diagnosis of CIU: Does the patient require the use of steroids to control urticarial symptoms? ☐ Yes – *Submit documentation.* ☐ No
7. **<u>For a diagnosis of CIU:</u>** Does the patient have a history of trial and failure, contraindication, or intolerance of all of the following at maximal tolerated doses? Check all that apply.
   ☐ H_1 antihistamine ☐ H_2 antihistamine ☐ leukotriene modifier ☐ dapsone, sulfasalazine, or hydroxychloroquine
   ☐ Yes ☐ No
   Submit documentation.
8. Will the patient be monitored and/or treated for helminth infection as recommended in package labeling? ☐ Yes ☐ No

RATIONALE FOR HOSPITAL OUTPATIENT FACILITY TREATMENT SETTING (if applicable):

☐ Documented history of severe adverse reaction occurred during or immediately following an infusion and/or the adverse reaction did not respond to conventional interventions

☐ Documentation that the member is medically unstable for the safe and effective administration of the prescribed medication at an alternative site of care as a result of one of the following:
- ☐ Complex medical condition, status, or therapy requires services beyond the capabilities of an office or home infusion setting (clinical instability or a complex regimen that requires frequent clinical assessment or monitoring, which would be beyond the capabilities of an office or home infusion setting)
- ☐ Documented history of medical instability, significant comorbidity, or concerns regarding fluid status inhibits treatment at a less intensive site of care (unstable fluid status associated with heart failure or advanced [stage 4 or 5] renal failure)

RENEWAL REQUESTS

1. **<u>For a diagnosis of asthma,</u>** has the patient experienced measurable evidence of improvement in asthma severity? ☐ Yes ☐ No
   Submit documentation of response to therapy.
2. **<u>For a diagnosis of chronic idiopathic urticaria,</u>** does the patient have documentation of improvement in symptoms and rationale for continued use of Xolair? ☐ Yes ☐ No
   Submit documentation of response to therapy and rationale for continued use.
3. Will the patient be monitored and/or treated for helminth infection as recommended in package labeling? ☐ Yes ☐ No

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:	Date:

<u>Confidentiality Notice:</u> The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.